Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Gern seems to be hiring a lot of people. Check their website.
No Impact on Human Embryonic Stem Cell Therapeutic Product Development
MENLO PARK, Calif., Nov. 21, 2007 ? Geron Corporation (Nasdaq: GERN) today commented on the impact of recent advances in cellular reprogramming on the development of human embryonic stem cell (hESC)-based therapies.
Advances in Cellular Reprogramming
As reported yesterday, two laboratories have generated what appear to be pluripotent stem cell lines from human skin cells by permanently introducing a number of specific gene sequences into the genome via live viral vectors. The resulting ?induced? pluripotent stem cell lines (iPS) expressed genes characteristic of ?embryonic? human stem cell lines, proliferated in vitro at small scale for several months and displayed the ability to form teratomas and to undergo differentiation in vitro to several functional cell types. Although the iPS cells appear similar to human embryonic stem cells, they differed from hESCs in global gene expression patterns, with over 1000 genes differentially expressed, and they have not been extensively characterized.
No Impact on hESC Therapeutic Product Development
?This is beautiful science,? said Thomas Okarma, Ph.D., M.D., Geron?s president and CEO. ?These findings contribute to a better understanding of the molecular biology of cellular differentiation. The work will enable the generation of pluripotent lines from individuals who suffer from poorly understood genetic diseases. Such lines will be useful in understanding how certain abnormal genes induce dysfunction in particular cell types that lead to disease.?
?Yet the results are unlikely to impact the development of stem-cell based therapeutics,? continued Dr. Okarma. ?The notion of using an individually derived pluripotent stem cell line as the source for the manufacturing of a therapeutic cell type used only for that individual is not only extremely labor intensive and technically difficult, it is economically unfeasible. Moreover, the often stated reason to make individual lines is to avoid immune rejection as in organ transplantation. However, immune rejection may not pertain to cells manufactured from hESCs, as we have shown recently with our OPC1 cells, our hESC-based therapeutic for spinal cord injury. These therapeutic cells made from hESCs are immune-privileged and are not recognized by the human immune system in vitro (Journal of Neuroimmunology, December 2007, 192(1-2): 134-144).?
?What is most important to recognize is that an undifferentiated stem cell is not a therapeutic cell,? said Dr. Okarma. ?Geron has the preeminent global leadership position using our own patented technologies developed over many years to scalably and reliably manufacture therapeutic (differentiated) cells from pluripotent stem cell lines, regardless of their source. Indeed, one of the two labs successfully used Geron?s proprietary methods (Nature Biotechnology, September 2007, 25(9): 1015-1024) in order to produce cardiomyocytes from their iPS cell lines derived from human skin.?
Geron is developing first-in-class biopharmaceuticals for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure and diabetes. The company is advancing an anti-cancer drug and a cancer vaccine that target the enzyme telomerase through multiple clinical trials. Geron is also the world leader in the development of human embryonic stem cell-based therapeutics, with its spinal cord injury treatment anticipated to be the first product to enter clinical development. For more information, visit www.geron.com.
Cusac has over 50 years of experience if you factor in the old man who turned it over to his son. Experience didn't help them.
Mining is a bunch of liers standing around a hole saying "looks like gold to me" My shares aren't worth much now so I'll just hold and wait.
I guess its better than filing for bankruptsy. Cusif couldn't make it even with gold at all time highs.
Finally maybe its the beginning of a big move up, then up again and again. This could be a $50 stock within a year..
NENG down 8% on decent volume either a shakeout or insiders bailing..Lets hope for a shakeout.
Alliance provides specialized service offerings based on your application requirements for the Military, Aerospace, and Government (MAG) sectors. Our MAG team leverages its expertise in technology, systems integration, and infrastructure optimization to integrate next-generation technology solutions. The MAG Unit adds expertise in project management, hardware and software design, documentation, and system test deployment to provide a complete end-to-end solution while providing maximum return on investment. The $20 Bil Gov Networx
program might come into play maybe thats what they have their sights set.
Wahz, What do you think of the NENG deal?
It's amazing that gold is at $700+ and cusif sits at .15.
Analysts at WBB Securities maintain their "strong buy" rating on Geron Corporation Inc (GERN.NAS). The 12-month target price has been raised to $16.50.
In a research note published this morning, the analysts mention that the company and its scientific collaborators have announced success in a lab test, which is likely to result in the development of a hESC product for repairing human hearts damaged by myocardial infarction. Geron is now going to test the mixture of proteins and stem cells in larger animals and the results are expected by mid-2008, the analysts say. Geron’s share price does not reflect an acquisition premium, although the company could become a target due to its unique position in both hESC and Telomerase, WBB Securities adds
This article also ran on National Public Radio today. Good for all who suffer.
NENG seems to be in rally mode maybe good news on the horizon!
NENG-A company called Trinad Capital Fund has bought over a million shares in the $1.80 area. Not sure if that good or bad
but maybe something is up..
Zeev, What's your take on HAUP? They seem to want to keep it below $5. Are you buying or bailing? Do you see a bottom here?
Thanks
SONS- I bet they ask for another extention..There are some good size sell orders. They must know something.
Ameritrade won't let you trade it online you have to use a broker. Never heard of that before. MCZ
Sons AH! SWEET!!!
They lost their biggest customer which accounted for almost $6 mil of their $10 mil in revs. Not good!
During the nine months ended March 31, 2007, Ningbo Dragon generated revenues of $9,965,382, as compared to revenues of $10,341,050 for the nine months ended March 31, 2006, a decrease of $375,668. This decrease is a result of the loss of a customer, Indonesia APP Group Company, during the current quarter. For the nine months ended March 31, 2007 this customer accounted for approximately $5,824,000. For the nine months ended March 31, 2006 this customer accounted for approximately $6,200,000 of revenues.
GERN- This looks like a pretty solid move on heavy vol.If we get follow thru tomorrow we could be on a major move up. What's your take on it.
Court Clears Way for Stem Cell Grants
Published: 5/16/07, 10:05 PM EDT
By JASON DEAREN
SAN FRANCISCO (AP) - The California Supreme Court cleared the way for the state's stem cell research agency to distribute billions of dollars in grants when it turned back a last-ditch legal challenge Wednesday.
The state's high court declined to review a lower court ruling that upheld the constitutionality of the California Institute for Regenerative Medicine. The litigation had prevented the agency from doling out $3 billion in research grants.
"Today's action by the California Supreme Court is a victory for our state because potentially life-saving science can continue without a shadow of legal doubt," said Gov. Arnold Schwarzenegger.
The resolution of the suit means the agency can now borrow money from Wall Street bond dealers. State Treasurer Bill Lockyer "intends to move as quickly as possible" in managing the sale of billions of dollars in bonds to fund research grants, said spokesman Tom Dresslar.
Robert Klein, who wrote the ballot initative that created the agency in 2004, said the court decision provides California with more resources for stem cell research than any other nation in the world.
The state high court had been asked by stem cell opponents to overturn the decision of a lower court, which had ruled in favor of the stem cell agency.
The plaintiff, the California Family Bioethics Council, had argued that the stem cell agency is corrupted by conflicts of interest. The council complained that university officials whose schools were applying for millions in research grants from the stem cell agency should not be on its oversight board.
As written, Proposition 71 dictates that those officials must recuse themselves when the board is considering an application from their schools.
Dana Cody, an attorney for the anti-abortion group Life Legal Foundation, another plaintiff, said she was not surprised by the ruling.
"I'm really sad that California taxpayers are going to be funding experimental research when there's been great strides made in adult stem cell research," she said.
Scientists hope human embryonic stem cells can someday be used to replace diseased tissue.
SONS could be at 10 by the end of the week if this vol keeps up. Sure would be a good time to release some good news..
Tuna, You still have drgg? If so is it worth hanging on to?
Thanks
GERN dropping premarket on larger 4th qtr losses. ouch! Might have to add if it gets below 6.50.
What's going on with SONS?
Sons, 8 + million shs and were up a penny. I don't get it??? Anybody have a take on what's going on?
Did you listen to SONS CC call? Sounded pretty good to me.
Zeev, What's your latest take on HAUP?
Thanks
Tuna What's your take on DRGG??
So sell before the news?? HAUP
Last year they released earnings Feb 10th so hopefully end of next week. I'm hoping for 27 to 30 mil and .12 to .15 ps.
HAUP we could see $10 before earnings next week...
Good News on NENG!! Maybe we finally go up and stay up..
MCZ looking weak. Good time to buy or did you get out?
Thanks
This could be the year for sons! Maybe we should fire this board up again? Stock is moving up and there is no resistance after 10.
So this crash is just a correction for a week or two then we head back up?
Then the shorts will be loading up..which would be good for longs if positive news hits next week. I'm holdin for 100 not a penny less..
Sons moving up on strong vol. Maybe we finally go for 10 after 10 its infinity and beyond!!!!I bet monday we get news.